FDA Approves Insys Therapeutics' 2nd Cannabis-Based Drug

On June 21, Todd Hagopian recommended Insys Therapeutics (INSY). Since then, the stock has gained nearly 20%. After a stock runs like this, many investors are tempted to sell. However, in situations like this, I've found it valuable to know which side of the trade the people with superior track records are on before making any trading decisions.